InventisBio Co (SHSE:688382) ROE % Adjusted to Book Value: -1.59% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688382 InventisBio Co Ltd SHSE:688382
29 GF Score
Price ¥25.99
GF Value ¥10.07
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is InventisBio Co ROE % Adjusted to Book Value?

InventisBio Co SHSE:688382 -0.19% 29 ROE % Adjusted to Book Value is -1.59% as of Mar. 2026. GuruFocus rates SHSE:688382 with a GF Score™ of 29/100 and a GF Value™ of ¥10.07 (Significantly Overvalued). The stock has 2 warning signs investors should review.

InventisBio Co's ROE % for the quarter that ended in Mar. 2026 was -11.71%. InventisBio Co's PB Ratio for the quarter that ended in Mar. 2026 was 7.35. InventisBio Co's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -1.59%.

InventisBio Co ROE % Adjusted to Book Value Related Terms

InventisBio Co ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for InventisBio Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InventisBio Co ROE % Adjusted to Book Value Chart

InventisBio Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 -9.66 -3.09 -2.97 -1.85

InventisBio Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.06 -1.29 -1.36 -3.30 -1.59

SHSE:688382 vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, InventisBio Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InventisBio Co ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InventisBio Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where InventisBio Co's ROE % Adjusted to Book Value falls into.


SHSE:688382
29GF Score
InventisBio Co Ltd SHSE:688382
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InventisBio Co ROE % Adjusted to Book Value Calculation

InventisBio Co's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-18.93% / 10.26
=-1.85%

InventisBio Co's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-11.71% / 7.35
=-1.59%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -1.59% mean?
InventisBio Co (SHSE:688382) has a ROE % Adjusted to Book Value of -1.59% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on InventisBio Co and its competitors.
Is InventisBio Co's ROE % Adjusted to Book Value too high?
InventisBio Co's current ROE % Adjusted to Book Value is -1.59%. Overall, InventisBio Co has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InventisBio Co's ROE % Adjusted to Book Value compare to VRTX and REGN?
InventisBio Co's ROE % Adjusted to Book Value of -1.59% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on InventisBio Co and its competitors. InventisBio Co's current ROE % Adjusted to Book Value is -1.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InventisBio Co stock overvalued right now?
Based on GuruFocus' analysis, InventisBio Co (SHSE:688382) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥10.07, compared to a current price of ¥25.99 — trading 158.1% above its estimated fair value. The current ROE % Adjusted to Book Value is -1.59%. InventisBio Co's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For InventisBio Co (SHSE:688382), the current ROE % Adjusted to Book Value is -1.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InventisBio Co (SHSE:688382) Overvalued in 2026?

Based on GuruFocus' analysis, InventisBio Co stock appears to be overvalued. The current stock price of ¥25.99 is trading 158.1% above its estimated GF Value™ of ¥10.07. GuruFocus considers InventisBio Co to be Significantly Overvalued.

Key valuation signals for SHSE:688382:

  • ROE % Adjusted to Book Value: -1.59%
  • GF Value™: ¥10.07 vs. price of ¥25.99 (158.1% above fair value)
  • GF Score™: 29/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688382 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InventisBio Co Business Description

Address No. 4, Lane 67, Li Bing Road, Room 210, Pilot Free Trade Zone, Shanghai, CHN, 201203
InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.
29GF Score

Get the complete analysis for SHSE:688382

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥25.99
Price
¥10.07
GF Value